Towards a non-invasive molecular test for bladder cancer

膀胱癌的非侵入性分子检测

• 批准号: 7305500
• 负责人: Steve Goodison
• 金额: $ 27.93万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-01 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7305500
• 关键词: Biological; Biological Assay; Biological Markers; Bladder; Bladder Neoplasm; Body Fluids; Cancer Detection; Characteristics; Chemistry; Clinic; Clinical; Complement; Complex; Cystoscopy; Cytology; Data; Detection; Development; Diagnosis; Diagnostic; Early Diagnosis; Generations; Glycoproteins; Gold; Health Care Costs; Healthcare Systems; Individual; Informatics; Invasive; Investigation; Lead; Liquid substance; Malignant Neoplasms; Malignant neoplasm of urinary bladder; Maps; Medical Surveillance; Methods; Molecular; Molecular Profiling; Pathologic; Patients; Phase; Population; Procedures; Protein Isoforms; Proteins; Proteomics; Public Health; Recurrence; Sampling; Screening procedure; Standards of Weights and Measures; Techniques; Testing; Tumor Biology; Urinalysis; Urination; Urine; Urology; Validation; base; follow-up; high throughput analysis; improved; insight; novel; software development; tumor; two-dimensional; urinary

DESCRIPTION (provided by applicant): The recurrence phenomenon of superficial bladder tumors makes bladder cancer one of the most prevalent cancers world-wide and is therefore a great burden to healthcare systems. Patients with superficial tumors are under continued surveillance by routine cystoscopy examinations of the bladder for early detection of new tumor developments. This is due to the lack of clinically useful markers which can detect the presence of bladder cancer without invasive procedures. Consequently, the development of urinalysis assays using reliable diagnostic markers would be of tremendous benefit to both patients and healthcare systems. This proposal aims to define molecular signature(s) of bladder cancer based on proteomic expression profiles. The protein complement of urine samples will be profiled using a novel combination of two-dimensional, liquid-phase separation and downstream mass mapping techniques. Data comprised of both quantitative and structural information will be correlated with clinical and pathological parameters. Thus, the proposed investigation will identify molecular profiles which are indicative of the presence of bladder cancer. Public health impact: The project seeks insights that will enable improvements in the non-invasive diagnosis of bladder cancer, through analysis of naturally voided urine. This will avoid unnecessary cystoscopy and therefore reduce patient discomfort and reduce health costs. Furthermore, the establishment of an accurate urine-based assay could lead to the development of routine screening of the population.

描述（由申请人提供）：浅表性膀胱肿瘤的复发现象使膀胱癌成为全球最常见的癌症之一，因此给医疗保健系统带来了巨大的负担。通过对膀胱进行常规膀胱镜检查来持续监测浅表肿瘤患者，以便及早发现新的肿瘤发展。这是由于缺乏临床上有用的标记物可以在不进行侵入性手术的情况下检测膀胱癌的存在。因此，使用可靠的诊断标记物进行尿液分析检测的开发将为患者和医疗保健系统带来巨大的好处。该提案旨在根据蛋白质组表达谱定义膀胱癌的分子特征。将使用二维、液相分离和下游质量图技术的新颖组合来分析尿液样本的蛋白质补充物。由定量和结构信息组成的数据将与临床和病理参数相关。因此，拟议的研究将鉴定表明膀胱癌存在的分子谱。 公共健康影响：该项目寻求通过分析自然排泄的尿液来改进膀胱癌的非侵入性诊断的见解。这将避免不必要的膀胱镜检查，从而减少患者的不适并降低健康成本。此外，建立准确的尿液检测方法可能会促进人群常规筛查的发展。